Delta-Fly Pharma Raises Funds Through Subscription Warrants and Unsecured Bonds

TOKYO, Jul 22 (Pulse News Wire) – Delta-fly Pharma,inc. (4598.T) raised funds through the issuance of subscription warrants and unsecured bonds to support research and development activities.

The total amount raised via the twelfth series of subscription warrants is approximately ¥1.270 billion (initial exercise price basis). The potential dilution rate is 75.90%. The rights exercise period spans two years, from August 10, 2026, to August 10, 2028. Additionally, the company issued third-party unsubordinated bonds worth ¥150 million, maturing on August 10, 2028.

The proceeds will be allocated towards various projects, including clinical phase I/II trials for DFP10,917+VEN combination therapy and phase III trial costs for DFP-14323, totaling ¥750 million and ¥326 million respectively. Other allocations include phase III trial costs for DFP-11207's biliary cancer physician-led trial, costing ¥50 million, and general pipeline research and development expenses, management fees, and patent-related expenditures, totaling ¥120 million. The financing structure allows immediate cash inflow through bond issuance while securing future funding needs via subscription warrants. The warrant exercise prices will adjust based on the lowest closing value of the previous three trading days multiplied by 100%, ensuring flexibility in raising capital according to market conditions.